Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EBT (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBT for 11 consecutive years, with -$77.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 218.7% to -$77.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$136.8 million, a 274.75% decrease, with the full-year FY2025 number at -$139.5 million, down 80.84% from a year prior.
  • EBT was -$77.4 million for Q4 2025 at Cartesian Therapeutics, down from -$19.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $15.0 million in Q2 2024 to a low of -$77.4 million in Q4 2025.
  • A 5-year average of -$11.5 million and a median of -$10.6 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 5505.67% in 2022, then tumbled 731.44% in 2023.
  • Cartesian Therapeutics' EBT stood at $12.4 million in 2021, then plummeted by 54.71% to $5.6 million in 2022, then crashed by 731.44% to -$35.4 million in 2023, then surged by 31.41% to -$24.3 million in 2024, then tumbled by 218.7% to -$77.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EBT are -$77.4 million (Q4 2025), -$19.5 million (Q3 2025), and -$20.1 million (Q2 2025).